PODIUM AGENDA (Subject to Change) Session 1

PODIUM AGENDA (subject to change)

Tuesday 10 th April 2018 | The Jarvis Doctorow Hall | St Edmund Hall | Oxford, UK

0830: Registration and coffee 0900: Welcome/housekeeping Session 1: Chair Mark Edbrooke 0915: Professor Tom Brown , University of Oxford, Oxford, UK Studies on Oligonucleotides with Chemically Modified backbones 0945: Dr Nebojsa Janjic , SomaLogic Inc, Boulder, CO, USA Base modifications play a key role in folding and binding of DNA aptamers to proteins 1015: Professor Rula Zain , Karolinska University Hospital, Karolinska Institutet, Sweden Disruption of non-B-DNA structures in triplet-repeat diseases using modified oligonucleotides 1045: Refreshments and Posters Session 2: Chair Tom Brown 1115: Dr Marcel Hollenstein , Institut Pasteur, Paris, France Expansion of the genetic code through the enzymatic construction of artificial metal base pairs 1145: Professor Elena Bichenkova , University of Manchester, Manchester, UK ‘Cleave and leave’ : catalytic oligonucleotide conjugates for future therapeutic applications 1215: Professor Ken Howard , Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, Denmark Albumin-based delivery of nucleic acid therapeutics: harnessing nature to cure disease 1245: Dr Emily Linnane , AstraZeneca R&D, IMED Oncology, Cambridge, UK Building Fundamental Mechanistic Insights into Antisense Oligonucleotide Uptake in Non-Small Cell Lung Cancer 1305 : Lunch (provided) and Posters Session 3: Chair Nebojsa Janjic 1400: Dr Mark Edbrooke, AstraZeneca R&D, IMED Oncology, Cambridge, UK High-affinity antisense oligonucleotides (ASOs) targeting Foxp3 inhibit the immunosuppressive function of regulatory T cells and produce anti-tumour effects in syngeneic tumour models 1430: Dr Linda Poppelwell , Royal Holloway-University of London, London, UK Combination antisense oligonucleotide treatments for Duchenne muscular dystrophy 1500: Professor Francesco Muntoni , UCL GOS Institute of Child Health, University College London, UK Splice switching antisense oligonucleotides in neuromuscular disorders 1530: Refreshments and Posters Session 4: Chair Rula Zain 1600: Professor Peter Zammit , King’s College London, London, UK Use of antisense oligonucleotide-mediated exon-skipping to remove a LMNA exon containing a pathogenic missense mutation causing laminopathy 1630: Dr Sylvain Ladame , Imperial College London, London, UK Engineered hydrogels for sensing of nucleic acid biomarkers in biofluids: a step toward new diagnostic tests for Cancer 1700: Professor Andrew Miller , Veterinary Research sInstitute, Hudcova, Brno, Czech Republic, and KP Therapeutics,, Manchester, UK Designing a future for RNA therapeutics and vaccines with Project FIT 1730: Dr Adrien Weingaertner, Silence Therapeutics GmbH, Berlin, Germany Development of innovative hepatocyte-targeted siRNA conjugates for the treatment of liver-related disorders. 1800: Discussion and close